Advaxis
[1] The company had over fifteen distinct constructs in various stages of development, directly developed by the company and through strategic collaborations with centers such as the National Cancer Institute, Cancer Research UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security, among others.The company had a veterinary medicine program that was evaluating an Lm-LLO-based immunotherapy in a Phase 1 study in canine osteosarcoma.[1]: 2 ,[4] Advaxis immunotherapies are based on a novel platform technology using live attenuated Listeria monocytogenes (Lm) that are bioengineered to secrete an antigen/adjuvant fusion protein.In 2009, Advaxis published the results of the first Phase 1 trial with the first Lm-LLO-based immunotherapy, ADXS-HPV in Vaccine (19 June 2009 / Volume 27, Issue 30).This study assessed side effects associated with increasing doses of ADXS-HPV in patients with metastatic, refractory, recurrent cervical cancer.